Dermatology Company Announces First Patient Enrollment In Netherton Syndrome Trial
Azitra has announced the screening and upcoming enrollment of the first patient in the Phase 1b trial of ATR-12, targeting Netherton Syndrome.
Azitra, Inc., a company specializing in precision dermatology, has recently announced a significant milestone in the development of ATR-12, its lead therapeutic candidate aimed at treating Netherton syndrome, a rare and severe genetic skin disorder. The company has successfully screened the first patient in its Phase 1b clinical trial, marking a crucial step forward in evaluating the potential of ATR-12 in addressing this debilitating condition. $Azitra (AZTR.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
NoNo444 : old news
Slooms NoNo444 : 21 hrs old is old news? O.o
NoNo444 : yeah, that's ancient history for internet![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Only Believe : Run it Champ![facepunch 👊](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f44a.png)
Benjamin’s : Bad trade. Lost I’m not even gonna hold this